NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer product candidates primarily for the treatment of various cancers; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone858-633-0300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$50,000.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date4/1/2019 (Estimated)
OptionableOptionable
Nantkwest (NASDAQ:NK) Frequently Asked Questions
What is Nantkwest's stock symbol?
Nantkwest trades on the NASDAQ under the ticker symbol "NK."
How were Nantkwest's earnings last quarter?
Nantkwest Inc (NASDAQ:NK) announced its quarterly earnings data on Monday, August, 15th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by $0.06. The biotechnology company earned $0.01 million during the quarter, compared to analyst estimates of $0.10 million. Nantkwest had a negative net margin of 200,500.02% and a negative return on equity of 55.78%. View Nantkwest's Earnings History.
When is Nantkwest's next earnings date?
What price target have analysts set for NK?
2 analysts have issued 12 month price objectives for Nantkwest's stock. Their forecasts range from $2.00 to $3.50. On average, they expect Nantkwest's share price to reach $2.75 in the next year. This suggests a possible upside of 67.7% from the stock's current price. View Analyst Price Targets for Nantkwest.
What is the consensus analysts' recommendation for Nantkwest?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nantkwest.
Has Nantkwest been receiving favorable news coverage?
News headlines about NK stock have trended negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Nantkwest earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days.
Who are some of Nantkwest's key competitors?
Some companies that are related to Nantkwest include MeiraGTx (MGTX), Scholar Rock (SRRK), Replimune Group (REPL), PDL BioPharma (PDLI), Mesoblast (MESO), DBV TECHNOLOGIE/S (DBVT), Avrobio (AVRO), Translate Bio (TBIO), Adaptimmune Therapeutics (ADAP), Agenus (AGEN), Solid Biosciences (SLDB), Krystal Biotech (KRYS), Adverum Biotechnologies (ADVM), Gritstone Oncology (GRTS) and Cellular Biomedicine Group (CBMG).
What other stocks do shareholders of Nantkwest own?
Who are Nantkwest's key executives?
Nantkwest's management team includes the folowing people:
- Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., FACS, Exec. Chairman & CEO (Age 66)
- Dr. Barry J. Simon, Pres, Chief Admin. Officer & Exec. Director (Age 54)
- Mr. Richard J. Tajak, Consultant (Age 66)
- Ms. Sonja Nelson, CFO & Principal Financial Officer (Age 46)
- Mr. David J. Pyrce, Chief Commercial Officer and Sr. VP of Innovation & Investor Relations (Age 62)
When did Nantkwest IPO?
(NK) raised $150 million in an IPO on Tuesday, July 28th 2015. The company issued 7,000,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray served as the underwriters for the IPO and MLV & Co. was co-manager.
Who are Nantkwest's major shareholders?
Nantkwest's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.20%), Geode Capital Management LLC (0.42%), Geode Capital Management LLC (0.42%), Candriam Luxembourg S.C.A. (0.29%), Dimensional Fund Advisors LP (0.29%) and Dimensional Fund Advisors LP (0.29%). View Institutional Ownership Trends for Nantkwest.
Which major investors are selling Nantkwest stock?
NK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp, Dimensional Fund Advisors LP and Dimensional Fund Advisors LP. View Insider Buying and Selling for Nantkwest.
Which major investors are buying Nantkwest stock?
NK stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., D. E. Shaw & Co. Inc., Two Sigma Investments LP, SG Americas Securities LLC, Paloma Partners Management Co, Rhumbline Advisers, Geode Capital Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Nantkwest.
How do I buy shares of Nantkwest?
Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nantkwest's stock price today?
One share of NK stock can currently be purchased for approximately $1.64.
How big of a company is Nantkwest?
Nantkwest has a market capitalization of $129.70 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-96,230,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.
What is Nantkwest's official website?
How can I contact Nantkwest?
Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]
MarketBeat Community Rating for Nantkwest (NASDAQ NK)
MarketBeat's community ratings are surveys of what our community members think about Nantkwest and other stocks. Vote "Outperform" if you believe NK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NK will underperform the S&P 500 over the long term. You may vote once every thirty days.
